Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
0–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Hospitalized with COVID-19 confirmed per a positive PCR of any specimen (e.g., respiratory, blood, urine, stool, or other bodily fluid) and evidenced by chest x-ray or CT scan
Receiving systemic corticosteroids at baseline
Oxygen saturation \< 93% on room air, or requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) to maintain oxygen saturation \> 92% at screening and baseline
You may not be if
Gestational age \< 37 weeks
Known severe allergic reactions to TCZ or other monoclonal antibodies
Active tuberculosis infection
Uncontrolled active bacterial, fungal, viral, or other infection (besides COVID-19)
Diagnosis or suspected diagnosis of multisystem inflammatory syndrome in children (MIS-C)
In the opinion of the investigator, progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatments
Have received oral anti-rejection or immunomodulatory drugs (including TCZ) within the past 3 months prior to enrollment
Treatment with an investigational drug within 5 drug-elimination half-lives or 30 days, whichever is longer, of enrollment (except for anti-SARS-CoV-2 antibodies or directly-acting antivirals)
Participating in another interventional drug clinical trial (except for anti-SARS-CoV-2 antibodies or directly-acting antivirals)
Clareo Health | A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19
